Lupin Ltd on Friday launched its generic version of Niaspan extended release tablets used in reducing cholesterol in the US market having received final approval from the US Food and Drug Administration (USFDA), it said in a statement.These tablets are generic equivalent of AbbVie Inc's Niaspan tablets.
Citing IMS MAT data, the company said Niaspan Tablets had annual sales of approximately $1 billion in the US in 2013.Niaspan tablets are used with diet to lower bad cholesterol while increasing the levels of good cholesterol in the body.
Citing IMS MAT data, the company said Niaspan Tablets had annual sales of approximately $1 billion in the US in 2013.Niaspan tablets are used with diet to lower bad cholesterol while increasing the levels of good cholesterol in the body.